MYGN Myriad Genetics Inc.

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Myriad to also host Investor Day in South San Francisco in September

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT.

On Sept. 19, Myriad will host an in-person at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco. Paul J. Diaz, president and CEO, and other members of the Myriad executive leadership team will discuss commercialization strategies, clinical advancement and new product pipeline, and long-term financial goals.

The Morgan Stanley fireside chat will be available on Myriad’s website at For those unable to attend Myriad’s Investor Day, the presentation and Q&A will also be available at .

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .  

Media Contact:

Glenn Farrell

(385) 318-3718



Investor Contact:

Matt Scalo

(801) 584-3532



EN
05/09/2023

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Rea...

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened—primarily...

August 13, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises ...

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-ov...

August 5, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Announces New $200 Million Credit Facility

Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an additional $75 million until June 30, 2027. This facility matures on July 31, 2030, and bears interest at a rate based upon the one-mo...

July 31, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Release Second Quarter 2025 Financial Results on Au...

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025. A live webcast of the conference call can be ...

July 29, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Earns 2025 Great Place To Work Certification™

Myriad Genetics Earns 2025 Great Place To Work Certification™ SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place To Work – 30 percentage points higher than the average U.S. company. “Our focus on inclusivity and caring makes this a great p...

July 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch